The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics

Register now for the Sept 26th AIRR Community Seminar

September 17, 2024 by Pam Borghardt

Registration for the September 26th (4:00 PM – 5:30 PM CET) AIRR-C Seminar Series session is open. Following the usual format of the series, an established and an early career scientist will discuss their AIRR-seq related research. Sol Efroni, of Bar Ilan University, Israel, will present “The T cell receptor core qualities, as seen by a language model.” Next, Giulio Isacchini, of Imprint, USA, will present “Generative Modeling of AIRRs with SoNNia.”

Register now!

Visit the AIRR Community Seminar Series website to learn more about this monthly series and access the recordings of past sessions.

Filed Under: AIRR Community

Results of the Imaging Calendar Competition announced!

September 9, 2024 by Silvia Crescioli

The Society’s Communication and Membership Committee is glad to announce that:
Eva Smorodina (University of Oslo and Oslo University Hospital, Norway) is the winner of our Imaging Calendar Competition! 
Congratulations!

The Imaging Calendar Competition ran from April 1st to July 15th 2024 and was open to all members. Participants submitted a high-resolution image with a brief explanation of the research behind it and the scientific method. This year we accepted both wet-lab and in-silico originated images.

Based on the results of our online poll, the winning image is “Getting closer to binding with every step” by Eva Smorodina (University of Oslo and Oslo University Hospital, Norway)

Image description: The image represents different levels of complexity surrounding antibody-antigen binding. We start from a more general understanding of the interaction kinetics with SPR, then identify the global binding site with cryo-EM, refine the region with HDX-MS to achieve peptide-level resolution, and move forward towards residue- and atom-wise resolution with computational techniques like docking and molecular dynamics. All these steps give us a better understanding of the structural rules behind antibody-antigen binding.

Antibodies used: Trastuzumab in complex with HER2

Instrument used: PyMOL, FoldX, IgFold

The winner will receive:

  • broad exposure of their work,
  • a $400 cash prize,
  • and the option of a free registration to: 1) Schrödinger’s online course, Introduction to Computational Antibody Engineering; 2) virtual Antibody Engineering & Therapeutics; or 3) 1 year subscription to the Oxford Global Plus platform.

The winning image will be featured as the cover image for the 2025 volume of mAbs, and also as the cover image of the calendar. The calendar will be distributed at the 2024 Antibody Engineering & Therapeutics, in San Diego, in December.

 

We are also glad to reveal the scientists behind the other short-listed images. These images will be included as well in The Antibody Society 2025 calendar, one every month.

Stefania Vilbois (University of Lausanne, Switzerland): Intravital mouse melanoma.

Jessica Anania (University of Southampton, UK): Follicular Dendritic Cell Organization in Germinal Centers for Immune Memory.

Andrew O’Connor (University of Southampton, UK): Inflammation in the mouse cochlea.

Rodrigo García Valiente (Amsterdam UMC, The Netherlands): Clonal fireworks.

Danielle Fails (Fortis Life Sciences, USA): Cells in Focus.

Shaoli Lin (National Cancer Institute, NIH, USA): Therapeutic antibody targeting GPC3 in liver cancer.

Suzanne Buss (University of Southampton, UK): Astrocytes – helping protect our brain.

Anthony Cheung (King’s College London, UK): Antibody-drug conjugates trigger microvesicle release ahead of endosomal internalization.

Alicia Chenoweth (King’s College London, UK): Heterogeneity of melanoma.

Filed Under: Competition, Uncategorized Tagged With: competition

Ordspono™ (odronextamab) approved in the European Union

August 26, 2024 by Janice Reichert

On August 26, 2024, Regeneron announced that the European Commission approved Ordspono™ (odronextamab) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. This marks the first regulatory approval of Ordspono in the world for these patients.

Odronextamab (REGN1979) is a hinge-stabilized, bispecific human IgG4k antibody targeting CD20 and CD3 with an Fc that was modified to reduce Fc receptor binding. The antibody was derived from Regeneron’s VelocImmune® technology and Veloci-Bi® platform and is being developed for the treatment of RR B-cell NHL. In 2020, Regeneron granted Zai Lab rights to develop and exclusively commercialize odronextamab in oncology in mainland China, Hong Kong, Taiwan, and Macau. Odronextamab received Fast Track designation from FDA and Orphan Drug designations by the FDA and EMA for the treatment of patients with FL and DLBCL, which are subtypes of NHL.

The approval in the European Union is based on results from the Phase 1 ELM-1 (NCT02290951)  and pivotal Phase 2 ELM-2 (NCT03888105) trials, which demonstrated robust, durable response rates in adults with R/R FL or R/R DLBCL

  • Results from ELM-1 (N=60) in R/R DLBCL patients who had progressed after CAR-T therapy, as assessed by an independent review committee (IRC) showed 48% objective response rate (ORR), with 32% achieving a complete response (CR). Among responders (n=29), the median duration of response (DoR) was 15 months (95% CI: 3 months to not estimable (NE)).
  • Results from ELM-2 (N=127) in R/R DLBCL patients who were CAR-T therapy naive, as assessed by an IRC showed 52% ORR, with 31% achieving a CR. Among complete responders the median DoR was 18 months (95% CI: 10 months to NE).
  • In R/R FL, results from ELM-2 (N=128) as assessed by an IRC showed an objective response rate (ORR) of 80%, with 73% achieving a CR. Among complete responders, the median DoR was 25 months (95% confidence interval [CI]: 20 months to NE).

Regeneron submitted biologics license applications (BLAs) for odronextamab for RR FL and DLBCL to FDA. In March 2024, Regeneron announced that the FDA issued complete response letters for the Biologics License Applications for odronextamab. The company noted that FDA’s only approvability issue is related to the enrollment status of the confirmatory trials.

Filed Under: Approvals Tagged With: antibody therapeutics, approved antibodies, European Medicines Agency, odronextamab

August 20, 2024 by Joshua Dorai


Announcing Leadership Changes and New Opportunities at The Antibody Society.


We are pleased to announce that Dr. Janice Reichert, who has served as our Chief Operating Officer, will be transitioning to a new role as Director of Business Intelligence. Janice’s leadership has been crucial to our success, and we are confident that she will continue to drive our mission forward in this new capacity.

Dr. Janice Reichert is an internationally recognized expert in the development of antibody therapeutics. She has been affiliated with The Antibody Society since 2010, serving on the Society’s Board of Directors and various committees, including as Executive Director and most recently as Chief Operating Officer. She is now transitioning to the role of Director of Business Intelligence.

Dr. Reichert created mAbs, a peer-reviewed, PubMed-indexed biomedical journal focusing on antibody research and development and has served as Editor-in-Chief since its inaugural publication in 2009. She has published extensively on development trends for antibody therapeutics and is particularly well known for creating the annual “Antibodies to Watch” articles, which have collectively been viewed nearly 290,000 times. Dr. Reichert has also presented her research at conferences worldwide. She received her Ph.D. in Chemistry from the University of Pennsylvania and completed her post-doctoral training at Harvard Medical School.

We wish Janice all the best in her new role!


Join Our Growing Team!


As we continue to expand, we are seeking a talented and experienced Business Manager to oversee all aspects of our organization’s financial and operational functions. If you have a strong background in business management and are passionate about joining our mission to enhance knowledge and understanding through information sharing and collaboration in the field of antibody research and development, we encourage you to apply.

Please send your resume to jobs@antibodysociety.org

For more information about the role, please refer to the detailed job description provided below.

  • LinkedIn
  • The Antibody Society Career Center

Looking Ahead.


We will be announcing additional new roles in the coming months. Be sure to watch this space for more opportunities to join our team.

Thank you for being a part of our community!

https://www.antibodysociety.org/the-antibody-society-org-news/18648/

Filed Under: The Antibody Society Org News

AIRR-C Meeting VII: A Landmark in AIRR Research!

July 14, 2024 by Pam Borghardt

The AIRR-C VII Meeting, held from June 3-6, 2024, at the Faculty of Engineering, University of Porto, Portugal, was a triumph, highlighting the latest in AIRR research. We delved into “Fundamental Immunological Processes and Human Diseases” through dedicated and groundbreaking discussions. Challenge sessions included Germline Gene Diversity where we explored interindividual variability in AIRRs with major implications for disease and vaccine prediction and Machine Learning Approaches which showcased AIRRs’ potential in predicting disease outcomes and discovering new therapeutic targets. 

Key Highlights

The success of AIRR-C VII was bolstered by the generous support of our 19 sponsors and partners, whose contributions were instrumental. We extend our heartfelt thanks to all who supported us. The event drew a diverse global audience with 182 in-person attendees and 31 remote participants from 26 countries, marking an increase from 2022. Our exceptional program featured 16 invited speakers, 10 contributed talks, 96 research posters, 11 Working Group and Sub-Committee posters, and a dynamic mix of sessions including 10 lightning demos and 9 deep dive tutorials. Participants engaged in hands-on, one-hour “deep dive” tutorials and short 10-minute “lightning” demonstrations of innovative software and tools, enhancing their technical skills and knowledge.

Early career researchers and students actively participated in career development activities alongside the scientific program. “Networking is in the AIRR” featured a speed networking event connecting early career scientists with established AIRR researchers, fostering invaluable connections across sectors and research areas. A career development panel discussion offered insights into diverse career paths within AIRR research, complementing the scientific sessions and providing opportunities for direct engagement with experts.

As part of the Industry Networking Reception, a special “hot topics in the field” round table session provided a unique opportunity for industry partners and scientific researchers to engage in exciting discussions. Moderated by pairs of AIRR-C Working Group Co-leaders and Industry Partners, these sessions focused on future needs and challenges in key areas such as “Antibody Discovery,” “AIRR-seq epitope/antigen annotation,” “Datasets and applications/tools for mining the repertoire,” “Biological Standards/Controls/Methods,” and “Data sharing & data standards for AIRR analysis and software.” The goal of these discussions was to gather input and ideas to shape the future of AIRR research.

Looking Ahead

AIRR-C VII has set a new standard for excellence. We eagerly anticipate the AIRR-C VIII meeting in 2026, where we will continue driving the exciting advancements in immunogenetics.

For more information, visit [Event Website] or contact us at [Contact Information] or follow us at #AIRRC8.

Filed Under: AIRR Community

« Previous Page
Next Page »

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Zooming into the Community III Starts Tomorrow! May 20, 2025
  • Exciting news – The AIRR Community is turning 10! 🎂 May 8, 2025
  • The Antibody Society (TAbS): Win a FREE Attendance Pass to AET Basel & Present A Poster: Call For Abstracts! March 26, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals